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Abstract
Purpose The aim of this study was to assess the test-retest
variability of [11C]PIB studies in patients with Alzheimer’s
disease (AD) and healthy controls using several tracer
kinetic models and to assess the suitability of the cerebellum
as reference tissue.
Methods [11C]PIB studies with arterial sampling were
performed in eight AD patients and eight healthy controls.
Retest scans were performed in six controls and six AD
patients. Data were analysed using plasma input and
reference tissue models, together with simple ratios.
Results Test-retest variability was best (∼3%) for SRTM2, a
parametric method based on the simplified reference tissue
model. Highest values (∼10%) were found for plasma input
models. Cerebellar VT values did not differ significantly
between AD and controls.
Conclusion Parametric SRTM2 with the cerebellum as
reference tissue is the method of choice for quantitative
analysis of [11C]PIB PET studies.
Keywords Pittsburgh compound B . PIB . Arterial
sampling . Cerebellum . Parametric images . Amyloid . PET
Introduction
Amyloid beta (Aβ) is the main constituent of amyloid
plaques in the brain of Alzheimer’s disease (AD) patients. It
is thought to be a key component of AD pathology [1].
With the development of new treatments for AD, aimed at
either preventing Aβ deposition or increasing its clearance,
the role of quantification of Aβ burden in vivo becomes
crucial [2, 3].
Over the past two decades several positron emission
tomography (PET) tracers have been developed for imaging
and quantifying fibrillar Aβ accumulation in AD in vivo.
Of these, N-methyl-[11C]2-(4’methylaminophenyl)-6-
hydroxybenzothiazole ([11C]PIB) [4] has been used most
widely. Several tracer kinetic models for quantification of
[11C]PIB binding have been reported [5, 6], although Logan
graphical analysis [7] and standardized uptake value ratios
(SUVr) have been used most frequently [5].
The reliability of [11C]PIB tracer kinetic models can be
assessed using test-retest studies. Good test-retest variabil-
ity is particularly important when evaluating the natural
time course of Aβ depositions and for monitoring thera-
peutic effects of novel drugs designed to reduce Aβ
accumulation in the brain. Data on test-retest variability of
[11C]PIB tracer kinetic models are confined to three studies,
mostly dedicated to simplified approaches [5, 6, 8]. In
addition, most clinical studies published to date have used
simplified analysis approaches with cerebellum grey matter
as reference region. Whilst the cerebellum is reported to be
free of Congo red and thioflavin S-positive plaques, diffuse
amyloid deposits are commonly observed [9, 10], especial-
ly in AD. Although these diffuse amyloid deposits in the
cerebellum were not detectable in a 6-CN-PiB staining
study [11], more data on cerebellar [11C]PIB binding in
vivo are necessary. This is especially important for those
Eur J Nucl Med Mol Imaging (2009) 36:1629–1638
DOI 10.1007/s00259-009-1129-6
N. Tolboom :M. Yaqub :R. Boellaard :G. Luurtsema :
A. D. Windhorst :A. A. Lammertsma :B. N. M. van Berckel
Departments of Nuclear Medicine & PET Research,
VU University Medical Centre,
Amsterdam, The Netherlands
N. Tolboom (*) : P. Scheltens
Department of Neurology & Alzheimer Centre,
VU University Medical Centre,
P.O. Box 7057, 1007 Amsterdam, MB, The Netherlands
e-mail: n.tolboom@vumc.nl
analyses where the cerebellum is used as reference tissue,
as binding of [11C]PIB to diffuse amyloid could lead to
underestimation of regional specific binding.
Only limited information is available describing binding
of [11C]PIB in the cerebellum in vivo. In two studies [5, 6]
published to date, the volume of distribution of [11C]PIB in
the cerebellum (VT) was similar for AD patients and
controls. It should be mentioned, however, that the first of
these studies only had limited power.
The aim of the present study was twofold. The first aim
was to further assess test-retest variability of [11C]PIB
studies using several modelling approaches. The second
aim was to investigate binding of [11C]PIB in the
cerebellum in order to evaluate whether it can be used as
reference tissue for [11C]PIB studies in AD.
Materials and methods
Participants
Eight AD patients [three women, five men, Mini-Mental
State Examination (MMSE) 21±2, age 61±3, mean ± SD]
and eight healthy controls (three women, five men, MMSE
30±1, age 66±6) were included in this study. All
participants received a standard dementia screening that
included medical history, physical and neurological exami-
nations, screening laboratory tests, brain magnetic reso-
nance imaging (MRI), and extensive neuropsychological
testing. Final diagnosis was established by a multidisci-
plinary team, without knowledge of the PET results. All
AD patients met NINCDS-ADRDA [12] criteria for
“probable AD”. Control subjects were recruited through
advertisements in newspapers and underwent the same
diagnostic procedures. Exclusion criteria for controls were
subjective memory complaints, a history of major neuro-
logical or psychiatric illness, or clinically significant
abnormalities on the MRI (as determined by a neuroradi-
ologist). Written informed consent was obtained from all
subjects after a complete written and verbal description
of the study. The study was approved by the Medical
Ethics Review Committee of the VU University Medical
Centre.
Radiochemical synthesis
Radiolabelled [11C]PIB was synthesized according to a
modification of the procedure described by Wilson
et al. [13]. The starting material 2-(4’-aminophenyl)-6-
hydroxybenzothiazole (4.1 µmol, 1.0 mg, purchased from
ABX, Radeberg, Germany) was dissolved in 250 µl of
acetone. To this solution [11C]methyl triflate [14] was
added at room temperature. After reaction at 60°C for 1
min, the reactionmixture was diluted with 750 µl of a solution
of trifluoroacetic acid (pH = 2) in water. This mixture was
injected onto a Chromolith RP18e 100*25mmHPLC column
(Merck, Darmstadt, Germany) which was eluted with a 50/50
mixture of trifluoroacetic acid (pH = 1.5) in water/methanol.
The product, [11C]PIB, eluted at 8 min. This fraction was
collected in 60 ml of water for injection. The total solution
was passed over a preconditioned (10 ml of 96% sterile
ethanol and subsequently 10 ml of water for injection) tC18
Sep-Pak (Waters, Milford, MA, USA). The Sep-Pak was
washed with a mixture of 5 ml of sterile ethanol in 15 ml of
water for injection to elute residual methanol from the HPLC
eluent and to elute an unidentified impurity. Finally, the
product was eluted from the Sep-Pak with 1.0 ml of sterile
ethanol (96%) and diluted with 14.0 ml of a sterile and
pyrogen-free solution of 7.09 mM NaH2PO4 in saline. This
final mixture was passed over a Millex GV 0.22-µm filter
(Millipore, Billerica, MA, USA), yielding a sterile, isotonic
and pyrogen-free solution of 1,491–3,997 MBq of [11C]PIB
with a (radio)chemical purity >98% and a specific activity
(SA) of 40–240 GBq/µmol at the end of synthesis.
PET
PET scans were performed on an ECAT EXACT HR +
scanner (Siemens/CTI, Knoxville, TN, USA), equipped
with a neuro-insert to reduce the contribution from outside
field of view (FOV) activity. This scanner enables the
acquisition of 63 transaxial planes over a 15.5-cm axial
FOV, thus allowing the whole brain to be imaged in a single
bed position. The characteristics of this scanner have been
described elsewhere [15]. [11C]PIB studies were performed
in 16 subjects: 8 AD patients and 8 healthy controls. Of
these subjects, six AD patients and six healthy controls
underwent repeat [11C]PIB studies. All repeat studies,
except for one, were performed on the same day. All
subjects received an indwelling radial artery cannula for
arterial blood sampling and a venous cannula for tracer
injection. Patient motion was restricted by the use of a head
holder and monitored by checking the position of the head
using laser beams.
First, a 10-min transmission scan was performed in 2-D
acquisition mode using three retractable rotating line
sources. This scan was used to correct the subsequent
emission scan for photon attenuation. Next, a dynamic
emission scan in 3-D acquisition mode was started
simultaneously with the intravenous injection of [11C]PIB
using an infusion pump (Med-Rad, Beek, The Netherlands)
in approximately 4 s followed by a flush of 40 ml saline at
2.0 ml/s. The average injected [11C]PIB dose for AD
subjects was 348±58 MBq (SA = 52±22 GBq/µmol) and
394±47 MBq [11C]PIB (SA = 53±22 GBq/µmol) for the
retest scans. For healthy controls, the average injected [11C]
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PIB dose for test scans was 347±25 MBq (SA = 53±
30 GBq/µmol) and 369±48 (SA = 50±18 GBq/µmol) for
the retest scans. Each dynamic emission scan consisted of
23 frames with progressive increase in frame length (1×15,
3×5, 3×10, 2×30, 3×60, 2×150, 2×300, 7×600 s) and a
total duration of 90 min. Arterial blood was withdrawn
continuously at a rate of 5 ml/min for the first 10 min and
2.5 ml/min thereafter until 60 min post-injection, using an
online detection system [16]. In addition, at 5, 10, 20, 30,
40, 60, 75 and 90 min post-injection, arterial blood samples
were collected manually. These were used to calibrate the
online blood curve, to determine plasma to whole blood
ratios of radioactivity and to measure plasma parent tracer
and metabolite fractions.
Finally, after a resting period of at least 1 h, on average
4 h and 32 min±8 min after the first administration to allow
for decay of [11C], exactly the same procedure was
repeated.
MRI
All subjects underwent a structural MRI scan using a 1.5 T
Sonata scanner (Siemens Medical Solutions, Erlangen, Ger-
many). The scan protocol included a coronal T1-weighted 3-D
MPRAGE (magnetization prepared rapid acquisition gradient
echo; slice thickness 1.5 mm, 160 slices; matrix size 256×
256; voxel size 1×1×1.5 mm; echo time = 3.97 ms; repetition
time = 2,700 ms; inversion time = 950 ms; flip angle 8°).
Metabolite analysis
Metabolite fractions were determined using online solid
phase extraction (SPE) combined with HPLC and radioac-
tivity detection [17]. A tC18 SPE online column was used in
combination with a 5-μm Gemini HPLC 5-μm C18 column
(250*10 mm, Phenomenex, Torrance, CA, USA). MeCN/
NH4OAc 10 mM [50/50 (v/v %)] was used as mobile phase
at a flow rate of 2.5 ml⋅min−1. The total recovery of [11C]
PIB from plasma using this method was >90% for all
samples. There was no time dependency with respect to
recovery of radioactivity. Retention times of 11C-labelled
metabolites and [11C]PIB were 10 and 15 min, respectively.
Image analysis
All PET sinograms were corrected for dead time, tissue
attenuation using the transmission scan, decay, scatter and
randoms and were reconstructed using a standard filtered back
projection algorithm and a Hanning filter with cut-off at 0.5
times the Nyquist frequency. A zoom factor of 2 and a matrix
size of 256×256×63 were used, resulting in a voxel size of
1.2×1.2×2.4 mm and a spatial resolution of approximately
7 mm full-width at half-maximum at the centre of the FOV.
ROI definition
MR images were aligned to corresponding PET images
using a mutual information algorithm [18]. Segmentation
of MRI and further analysis of the PET data was performed
using PVE-lab, a software programme that uses a
probability map of 35 delineated (grey matter) regions of
interest (ROI) that has been validated previously [19]. For
the present study, grey matter ROIs of frontal (volume-
weighted average of orbital frontal, medial inferior frontal
and superior frontal), parietal and temporal (volume-
weighted average of superior temporal and medial inferior
temporal) cortex and medial temporal lobe (MTL) (volume-
weighted average of enthorinal cortex and hippocampus),
posterior cingulate and cerebellum were used. In addition, a
“global cortical” ROI was defined, based on the volume-
weighted average of all the aforementioned regions except
the cerebellum. As the purpose of this study was to assess
intra-subject variability, no correction for partial volume
effects was applied.
Kinetic analyses
Kinetic analyses were performed using dedicated software
developed within Matlab 5.3 (The Mathworks, Natick, MA,
USA). The online blood curve was calibrated using the
manual whole blood samples. To this end, the interval of
the curve between first and last manual samples was fitted
to a multi-exponential function, adding exponentials until
both Akaike [20] and Schwarz [21] criteria indicated no
further improvement. The (original) online sampler curve
was then multiplied with the average of the ratios of (whole
blood) sample values and corresponding interpolated values
of the fitted exponential function. Next, the plasma to
whole blood ratios of the manual samples were also fitted
to a multi-exponential function, again using Akaike and
Schwarz criteria to determine the number of exponentials.
The (calibrated) whole blood curve was then multiplied
with this multi-exponential function to generate the
corresponding (total) plasma curve. Finally, the parent
fraction was fitted to a Hill function and the total plasma
curve was multiplied with this fitted function to obtain the
metabolite-corrected plasma input function
Plasma input method
ROI data were analysed using a reversible two-tissue
compartment (2T4k) plasma input model, including a
parameter for blood volume fraction [22] and providing
both binding potential (BP2T4k=k3/k4, which can contain a
non-specific component) and volume of distribution (VT).
In addition, the distribution volume ratio (DVR) with
cerebellar grey matter was calculated [DVR = VT(target)/
Eur J Nucl Med Mol Imaging (2009) 36:1629–1638 1631
VT(cerebellum)] [23]. Data were fitted using parameter
boundary constraints. Furthermore, an optimized non-linear
least-squares procedure was used [24]. According to this
procedure, parameter boundaries were estimated using
several runs, each time activity curve was fitted multiple
times using different starting parameters and the fit was
visually inspected afterwards. Note that, in order to
distinguish BP (k3/k4) derived from plasma input and
reference tissue models, BP2T4k will be used for the 2T4k
plasma input model, as it does not separate specific from
non-displaceable binding.
Reference tissue methods
In addition to the plasma input method, data were also
analysed using both reference tissue models and simple
ratios. First, BPND was derived for ROI data using the
simplified reference tissue method (SRTM) [25] with
cerebellar grey matter as reference tissue. With SRTM, for
k2 a lower bound of 0.006 was used, but no upper bound
was set. Next, parametric images of BPND were generated
using a basis function implementation of the “two-step”
SRTM [26]: parametric SRTM2 (also referred to as RPM2
in previous reports [27, 28]). In the first run, parametric
SRTM [29] was used to obtain an estimate of the reference
tissue efflux rate constant, k2′. To reduce noise, in the
second run (parametric SRTM2) k2′ was fixed to the median
(parametric SRTM) value for all pixels with BPND>0. For
both parametric SRTM and parametric SRTM2, 40 basis
functions were used. qmin3 ¼ k
min
2
1þBPmaxð Þ and q
max
3 ¼ kmax2 were
set to 0.01 and 0.3 min−1, respectively. This method was
chosen, as it has been identified as the parametric method of
choice [28].
Finally, data were analysed using SUV ratios (SUVr),
which is the target to grey matter cerebellum SUV ratio
over the interval 60–90 min after injection.
For all methods cerebellar grey matter was chosen as
reference tissue because of its (histopathological) lack of
Congo red and thioflavin S-positive plaques [9, 10].
Evaluation of methods and statistics
The p values for group differences were obtained using
Student’s t test.
Mean parameter values, test-retest variability and per-
centage difference between test and retest of [11C]PIB
studies in patients with AD and healthy controls was
assessed for 2T4k derived DVR, 2T4k BP2T4k+1 and VT,
and for SRTM derived BPND++1, parametric SRTM2
derived BPND+1 and SUVr. Test-retest variability was
assessed using BPND+1, similar to Price et al. [5], which
corresponds to DVR. This was done because BPND in
healthy controls approaches zero; therefore, small devia-
tions in values will lead to large relative variability. Intra-
subject test-retest variability was calculated as the absolute
difference between retest (R) and test (T): test/retest (%) =
100×absolute{(R-T)/( 0.5(R + T) )}. Percentage difference
between test and retest was calculated using: (%)=100×
{(R-T)/(T)}. Regional variability was further assessed for
VT, parametric SRTM2 derived BPND+1 and SUVr.
The relationship between 2T4k derived DVR and both
SRTM and parametric SRTM2 derived BPND+1, and
between SRTM derived BPND+1 and parametric SRTM2
derived BPND+1 was assessed using the square of the
Pearson’s product moment correlation coefficient (r2).
Average parietal and cerebellar 2T4k derived BP2T4k and
VT values were compared between AD patients and
controls.
Results
Arterial input function
Eight AD patients and eight healthy controls were included
of which six AD patients and six controls underwent repeat
scans. AD patients and healthy controls were similar with
respect to age (p value>0.05). All test and retest scans were
performed on a single day, except for one control subject,
who was scanned with an interval of 14 days due to
technical difficulties (radiosynthesis failure). Although
arterial blood sampling was performed in all subjects, due
to technical reasons, plasma input data were not available
for one control (retest) and two AD patients (both test and
retest) scans. Metabolite-corrected plasma input data were
acquired in six AD patients and eight controls. Complete
test-retest plasma input data were available for four of six
AD patients and five of six controls.
Test-retest data
Table 1 summarizes mean (±SD) parameter values of the
various methods for cortical areas known to be associated
with high (parietal cortex) and slightly less (sensory motor
cortex) [11C]PIB uptake. For the parietal cortex, differences
between AD and control values were assessed. Best group
differentiation was obtained using parametric SRTM2 (p<
0.01) and SUVr (p=0.01). Table 2 summarizes absolute
variability. Using absolute values, 2T4k (plasma input)
derived DVR and VT showed variability around ∼10%.
Using 2T4k BP2T4k+1 values in AD were ∼10% with
somewhat higher values in controls. SRTM derived BPND+
1 showed low variability in AD patients, but higher values
for controls (AD ∼4.5%; controls ∼12.5%). In contrast,
SUVr showed lower values for controls (∼5%) and slightly
higher values for AD (7–9%). Parametric SRTM2 derived
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BPND+1 had lowest variability for both controls and AD
(2–4%). Table 3 summarizes percent differences. The
smallest percent difference was seen using the reference
tissue approaches SRTM derived BPND+1 and parametric
SRTM2 derived BPND+1. There was a trend towards
higher values for retest scans in the AD patients for all
methods used, but this was not significant. For controls the
opposite was seen, but again this was not significant.
Next, regional variabilities of a plasma input method
(VT), a reference tissue method (parametric SRTM2) and a
simple ratio method (SUVr) were assessed. Figure 1 shows
test-retest variability of VT, parametric SRTM2 derived
BPND+1 and SUVr for several cortical regions, i.e. frontal,
MTL, temporal and parietal cortex, posterior cingulate,
together with values for the global cortical ROI. As
mentioned above, VT test-retest data were obtained for five
controls and four AD patients, and parametric SRTM2 and
SUVr data for six controls and six AD patients. For the
global cortical ROI, the highest variability was seen in VT
(AD: 9.8±8.2%; controls: 11.8±13.7%). Test-retest vari-
ability was lowest for parametric SRTM2 derived BPND+1
(AD: 3.0±2.9%; controls: 2.5±1.8%). SUVr yielded ac-
ceptable variability (AD: 8.0±7.0%; controls: 4.4±4.2%).
The same patterns were observed for other regions. All
methods showed the highest intra-test variability in MTL,
the ROI with the smallest size, but again variability of
parametric SRTM2 was better than that of the other models.
For none of the regions and none of the binding measures
were significant differences between AD patients and
controls found.
Overall, plasma input methods showed markedly higher
variability in both AD and controls compared with
reference tissue based methods. For all regions parametric
SRTM2 derived BPND+1 showed the best variability.
Correlation between plasma input and reference tissue
models
Good agreement (r2 0.85–0.87) was found between 2T4k
derived DVR and both SRTM and parametric SRTM2
derived BPND+1 (Fig. 2a and b, respectively). Data were
pooled over all subjects and all regions. Figure 2c illustrates
the expected good agreement (r2=0.93) between BPND+1
derived with SRTM and parametric SRTM2. It compares
BPND derived using parametric SRTM2 and SRTM, i.e.
with and without fixing the reference tissue efflux rate k2′.
Table 1 Mean (± SD) test and retest values of plasma input and reference tissue methods together with a simple ratio
ROI 2T4k (DVR) 2T4k (BP2T4k+1) 2T4k (VT) SRTM (BPND+1) Parametric
SRTM2 (BPND+1)
SUVr
Test Retest Test Retest Test Retest Test Retest Test Retest Test Retest
AD parietal 1.76
(0.48)
1.87
(0.39)
3.43
(1.05)
3.69
(0.88)
6.67
(2.05)
6.93
(1.69)
1.67
(0.35)
1.71
(0.32)
1.75
(0.36)
1.80
(0.33)
1.93
(0.49)
2.04
(0.40)
AD sensory
motor Cx
1.50
(0.44)
1.57
(0.33)
3.16
(1.01)
3.29
(0.78)
5.69
(1.88)
5.83
(1.49)
1.51
(0.30)
1.55
(0.35)
1.41
(0.25)
1.44
(0.24)
1.63
(0.41)
1.71
(0.32)
Control parietal 1.19a
(0.10)
1.14
(0.11)
2.77b
(0.96)
2.66
(1.12)
5.09c
(2.16)
4.94
(2.60)
1.32d
(0.22)
1.27
(0.23)
1.12e
(0.22)
1.09
(0.21)
1.25f
(0.18)
1.22
(0.18)
Control sensory
motor Cx
1.17
(0.06)
1.13
(0.08)
2.75
(0.99)
2.65
(1.12)
4.98
(2.02)
4.89
(2.52)
1.39
(0.25)
1.33
(0.18)
1.10
(0.13)
1.07
(0.13)
1.24
(0.12)
1.21
(0.12)
Compared to AD parietal: a p<0.05, b p=0.36, c p=0.30, d p<0.10, e p<0.01, f p=0.01
In the case of 2T4k, n=4 and 5 for Alzheimer patients and healthy controls, respectively; in the case of SRTM, parametric SRTM2 and SUVr n=6
for both patient groups
ROI region of interest, AD Alzheimer’s disease, Cx cortex
Table 2 Mean (± SD) absolute test-retest variability (%)
ROI 2T4k (DVR) 2T4k (BP2T4k+1) 2T4k (VT) SRTM (BPND+1) Parametric SRTM2 (BPND+1) SUVr
AD parietal 10.5 (10.0) 9.5 (11.0) 10.3 (8.9) 3.5 (3.3) 4.0 (3.7) 8.9 (8.0)
AD sensory motor Cx 11.1 (11.3) 9.2 (11.1) 12.5 (10.8) 5.5 (5.7) 2.3 (2.4) 8.9 (8.9)
Control parietal 9.9 (9.2) 12.7 (12.9) 11.4 (15.1) 11.5 (13.3) 2.4 (1.9) 4.7 (5.6)
Control sensory motor Cx 8.3 (8.2) 11.7 (7.4) 11.3 (9.3) 13.4 (18.6) 2.5 (2.8) 4.5 (7.5)
Number of subjects are identical to those given in Table 1
ROI region of interest, AD Alzheimer’s disease, Cx cortex
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Note, however, that SRTM was applied to ROI time activity
curves with low levels of noise, whilst in parametric
SRTM2 fitting was performed at the voxel level. The good
correlation seen in this figure indicates that parametric
SRTM2 can be used without loss of accuracy. Fixation of
k2′ is required for generating accurate parametric BPND
images.
Cerebellar data
In Fig. 3 2T4kderivedBP2T4k and VT values of cerebellum
grey matter and parietal cortex are given for AD patients (n=
6) and healthy controls (n=7). Data of one healthy control
was excluded because of a high value in the cerebellum.
Although average cerebellum BP2T4k and VT values for AD
subjects (0.96±0.24 and 3.85±0.70, respectively) were
somewhat higher than those for controls (0.79±0.21 and
3.24±0.55), there were no significant differences between the
groups (p=0.19 for BP2T4k and p=0.11 for VT). In contrast,
compared with controls, a twofold increase was found in the
parietal cortex of AD patients. VT of the parietal cortex in
controls was 3.79±0.63 and in AD patients 7.28±1.48 (p<
0.001). BP2T4k of the parietal cortex was 1.30±0.32 and 2.64±
0.66 in controls and AD patients, respectively (p=0.001).
Discussion
This study evaluated test-retest variability of [11C]PIB
studies using several modelling approaches. Test-retest
variability was markedly higher in methods using plasma
input data as compared to reference tissue methods, with
best variability for parametric SRTM2. The high test-retest
variability for plasma input methods was primarily due to
the higher number of fit parameters when including
fractional blood volume and additional uncertainty inherent
in the metabolite analysis. Average cerebellum BP2T4k and
VT values derived with the plasma input model showed no
significant differences between the groups, although slight-
ly higher values were observed in AD patients. As such,
cerebellum grey matter can be used as a reference tissue for
[11C]PIB studies in AD patients. In addition, parametric
SRTM2 is a stable and reliable method for quantifying
[11C]PIB binding, even when assessing small target
regions. Parametric SRTM2 with the cerebellum as refer-
ence region showed excellent test-retest variability and
good group differentiation and is therefore the method of
choice for quantifying [11C]PIB studies, especially when
addressing longitudinal follow-up or treatment response.
The uncertainty in the metabolite analysis is largely due
to rapid peripheral metabolism of [11C]PIB, leading to
negligible amounts of parent tracer at 90 min [28] and
consequently to increased uncertainty in the fits. 2T4k
derived DVR performed slightly better than BP2T4k+1 in
controls. This can be due to the fact that DVR is calculated
using VT(target)/VT(cerebellum) which could lead to more
stability at low values compared to other methods using
plasma input data.
When comparing absolute values obtained using SRTM,
parametric SRTM2 and 2T4k derived DVR, good agree-
ment was observed (Fig. 2). When comparing variability
between these methods, the better variability obtained with
parametric SRTM2 probably is due to the reduced number
of fit parameters as a result of fixing k2′. The poorer
variability of 2T4k derived might be due to the fact that this
parameter is derived from a ratio of two fitted parameters,
which might be more sensitive to error propagation.
Furthermore, the uncertainty inherent in the metabolite
analysis also contributes to the higher variability. Apart
from differences between methods, also differences be-
tween AD patients and controls and between regions were
seen. Differences in variability (Table 2) were less distinct
for the plasma input than for the reference tissue methods.
This may be due to noise from the metabolite correction or
result from the contribution of non-specific binding, which
in contrast to reference tissue methods may be incorporated
in BP2T4k. For SRTM variability was somewhat higher in
controls than in AD patients. This could be due to the lower
BPND in controls (and to some extent in sensory motor
cortex of AD), leading to relatively higher variability. With
parametric SRTM2 and SUVr the opposite pattern was
seen. In the case of parametric SRTM2 this could be a
Table 3 Mean (± SD) difference between test and retest (%)
ROI 2T4k (DVR) 2T4k (BP2T4k+1) 2T4k (VT) SRTM (BPND+1) Parametric SRTM2 (BPND+1) SUVr
AD parietal 9.1 (16.9) 10.5 (12.8) 6.8 (14.4) 2.7 (4.3) 2.2 (4.6) 7.5 (11.0)
AD sensory motor Cx 8.6 (14.1) 7.6 (15.2) 6.5 (18.3) 3.4 (8.0) 3.4 (2.6) 7.3 (12.4)
Control parietal −4.2 (11.3) −5.1 (13.9) −7.8 (11.9) −2.9 (17.0) −2.2 (2.1) −2.2 (6.7)
Control sensory motor Cx −3.3 (10.3) −4.9 (11.2) −7.2 (14.7) −1.5 (19.6) −2.1 (3.1) −2.4 (7.8)
Number of subjects are identical to those given in Table 1
ROI region of interest, AD Alzheimer’s disease, Cx cortex
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result of boundary conditions, inherent in the use of basis
functions, thereby reducing the possibility of erroneous fit
parameters, especially for low BPND. In the case of SUVr
this could possibly be an artefact as a result of differences
between subjects in reaching equilibrium. Differences in
percent (Table 3) showed a trend towards higher values for
retest scans in the AD patients, with the opposite pattern for
controls. Differences between test and retest scans were not
significant, possibly due to the limited power of the study
and the relatively large standard deviations found. Howev-
er, further research should assess if these trends are also
present and possibly even significant in a larger population.
Overall, test-retest variability was similar to that ob-
served for other radiotracers [30]. More importantly, it was
also in agreement with values reported earlier for [11C]PIB
studies [5, 6, 8]. Somewhat higher values for 2T4k derived
DVR were seen compared with an earlier test-retest study
of five subjects (two controls, one patient with mild
Fig. 2 Linear regression between 2T4k derived DVR-1 and a SRTM
derived BPND and b parametric SRTM2 derived BPND, and c between
SRTM and parametric SRTM2 derived BPND, all without fixed
intercept. Data are pooled over all subjects and all regions
Fig. 1 Test-retest variability is shown for a VT, b parametric SRTM2
derived BPND+1 and c SUVr of several regions of interest (ROI):
frontal, medial temporal, temporal and parietal cortex, posterior
cingulate and global cortical binding. The latter is the volume-
weighted average of the previously mentioned regions. In the case of
VT, n=4 and 5 for patients with Alzheimer’s disease (AD) and healthy
controls, respectively; in the case of parametric SRTM2 and SUVr, n=
6 for both patient groups. AD: filled columns; healthy controls: open
columns
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cognitive impairment and two AD patients) using arterial
based Logan DVR (calculated with VT) as outcome
measure [5]. These slightly higher values for variability
could be due to the fact that arterial based Logan VT is
sensitive to noise [31]. In another study, the same group
assessed several analytical methods and concluded that the
non-invasive Logan method showed the lowest test-retest
variability (5%) [6]. In the present study parametric SRTM2
showed the best variability. A direct comparison between
non-invasive Logan and parametric SRTM2 was made
previously [28], showing that reference Logan was slightly
more “biased” than parametric SRTM2 because of its
weaker correlation with BP2T4k derived from 2T4k and
BPND derived from SRTM.
For clinical studies, low test-retest variability is impor-
tant especially for smaller ROI. Whilst in full-blown AD
amyloid load is spread throughout the brain [1], in
preclinical AD early depositions are more localized. In
familial AD this has been reported to be in striatum [32],
while in non-demented “PIB-positive” subjects the highest
values have been reported in the precuneus [33]. In the
present study, parametric SRTM2 had the best test-retest
variability, not only for the global cortical ROI, but also for
smaller ROI. Therefore, parametric SRTM2 is a stable and
reliable method for quantifying [11C]PIB uptake reflecting
early amyloid deposition.
To date, most clinical [11C]PIB studies have used the
cerebellum as reference tissue for analysing PET data. The
use of the cerebellum as reference tissue has circumvented
the need for a metabolite-corrected arterial plasma input
function. This is important because arterial sampling in
general and in AD patients in particular is challenging.
Nevertheless, to be able to assess specific [11C]PIB binding
in the cerebellum arterial sampling is necessary. The present
study is one of the few in patients with AD where plasma
input data were available.
An ideal reference tissue should have a negligible
concentration of specific binding sites. In the present study,
average cerebellar BP2T4k was close to 1 for both AD
patients and healthy controls. Although this finding in itself
could argue against the use of the cerebellum as reference
tissue, BP2T4k and VT values between both groups did not
differ significantly, suggesting non-specific binding (bind-
ing other than to fibrillar amyloid) as the major component
of cerebellar BP2T4k. It should be noted that the lack of
power due to a limited number of subjects could have
affected results. Although they did not differ significantly,
average values for cerebellum BP2T4k and VT in this group
of mild AD patients were somewhat higher than in controls.
If this (minor) difference is indeed due to diffuse amyloid
deposits in the cerebellum of AD patients, this could lead to
underestimation of specific binding in the target region
when using the cerebellum as reference region. In cross-
sectional (e.g. diagnostic) studies, minor underestimation is
unimportant, as the difference in specific binding between
target (e.g. cortical) and reference regions would be high.
For longitudinal studies and studies in preclinical AD
patients, however, it could become important. If there is an
increase in amyloid depositions in the cerebellum with
progression of AD, it would lead to progressive underes-
timation of the amyloid load over time. Future studies
should focus on evaluating VT in the cerebellum of AD
patients over time in order to validate it as a proper
reference region.
Fig. 3 Scatter plots showing the distribution of individual subject
2T4k derived values of a BP2T4k and b VT for cerebellum (squares)
and parietal cortex (triangles) using plasma input data of six patients
with Alzheimer’s disease (AD) (filled symbols) and seven healthy
controls (open symbols). Cerebellar BP2T4k and VT did not differ
significantly between AD patients and healthy controls (BP2T4k p=
0.19, VT p=0.11 ). Compared with controls a twofold increase was
found in AD patients in the parietal cortex (BP2T4k p<0.001, VT p=
0.001)
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Conclusion
The results of this study underscore the validity of parametric
SRTM2 as the method of choice for quantifying [11C]PIB
PET data, especially in longitudinal studies. In addition,
data suggest that cerebellar grey matter can be used as
reference tissue in [11C]PIB studies, although further
studies are needed to assess whether there is a minor
degree of specific uptake in the cerebellum of AD patients.
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